dbo:abstract
|
- Nancy A. Thornberry is the founding CEO and current Chair, R&D at Kallyope Inc. in New York City. She previously worked with Merck Research Laboratories (MRL), joining the company in 1979 as a biochemist and retiring from the position of Senior Vice President and Franchise Head, Diabetes and Endocrinology in 2013. In 1992, Thornberry identified the first caspase, Caspase-1/Interleukin-1 converting enzyme (ICE). In 1999, Thornberry initiated Merck's research into dipeptidyl peptidase-4, leading to the development of FDA-approved treatments for Type 2 diabetes. She has received a number of awards, including the 2011 PhRMA Discoverer’s Award. (en)
|
dbo:almaMater
| |
dbo:nationality
| |
dbo:residence
| |
dbo:thumbnail
| |
dbo:wikiPageExternalLink
| |
dbo:wikiPageID
| |
dbo:wikiPageLength
|
- 16689 (xsd:nonNegativeInteger)
|
dbo:wikiPageRevisionID
| |
dbo:wikiPageWikiLink
| |
dbp:align
| |
dbp:almaMater
| |
dbp:awards
| |
dbp:caption
|
- Nancy Thornberry, 2017 (en)
|
dbp:field
|
- Metabolic disorders, Drug discovery (en)
|
dbp:name
|
- Nancy Ann Thornberry (en)
|
dbp:nationality
| |
dbp:residence
| |
dbp:video
|
- “Bench to bedside -- discovery of JANUVIA (Sitagliptin)”, Ann Weber & Nancy Thornberry, TEDxNJIT (en)
- “PhRMA11 Discoverers Award Winner 2011”, PhRMAPress (en)
|
dbp:width
| |
dbp:wikiPageUsesTemplate
| |
dbp:workInstitutions
|
- Kallyope Inc., Merck Research Laboratories (en)
|
dcterms:subject
| |
rdf:type
| |
rdfs:comment
|
- Nancy A. Thornberry is the founding CEO and current Chair, R&D at Kallyope Inc. in New York City. She previously worked with Merck Research Laboratories (MRL), joining the company in 1979 as a biochemist and retiring from the position of Senior Vice President and Franchise Head, Diabetes and Endocrinology in 2013. (en)
|
rdfs:label
| |
owl:sameAs
| |
prov:wasDerivedFrom
| |
foaf:depiction
| |
foaf:isPrimaryTopicOf
| |
foaf:name
|
- Nancy Ann Thornberry (en)
|
is dbo:wikiPageDisambiguates
of | |
is dbo:wikiPageWikiLink
of | |
is foaf:primaryTopic
of | |